Skip to main content
Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
10.55
+0.57 (5.71%)
At close: Mar 9, 2026, 4:00 PM EDT
10.48
-0.07 (-0.66%)
After-hours: Mar 9, 2026, 5:45 PM EDT

Novavax Revenue

In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth. Novavax had revenue of $147.14M in the quarter ending December 31, 2025, with 66.61% growth.

Revenue (ttm)
$1.12B
Revenue Growth
+64.69%
P/S Ratio
1.53
Revenue / Employee
$1,499,972
Employees
749
Market Cap
1.72B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.12B441.32M64.69%
Dec 31, 2024682.16M-301.54M-30.65%
Dec 31, 2023983.71M-998.17M-50.36%
Dec 31, 20221.98B835.58M72.89%
Dec 31, 20211.15B670.69M141.02%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Harmony Biosciences Holdings 868.45M
Innoviva 411.33M
Immunocore Holdings 400.02M
AnaptysBio 234.60M
Intellia Therapeutics 67.67M
Nuvation Bio 62.90M
Agios Pharmaceuticals 54.03M
Nanobiotix 11.93M
Revenue Rankings

NVAX News

More News